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Abstract
Objective
To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) fol-
lowed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-
naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through
the influence of thymidylate synthase (TS) protein and mRNA expression on several out-
comes. The primary endpoints were the overall response rate (ORR), progression-free sur-
vival (PFS) and overall survival (OS).
Methods
A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0
mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four
cycles. Maintenance PB was administered until disease progression or unacceptable
toxicity.
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Results
One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a
median number of 6 maintenance cycles (range, 1–32) were assessed. The ORR among
the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9
months (95% CI, 5.9–10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respec-
tively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutrope-
nia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities
were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxi-
city (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension
cases were reported. OS was significantly higher in patients with the lowest TS mRNA lev-
els [median, 29.6 months (95% CI, 26.2–32.9)] compared with those in patients with higher
levels [median, 9.3 months (95% CI, 6.6–12.0); p = 0.0001]. TS expression (mRNA levels or
protein expression) did not influence the treatment response.
Conclusion
Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tol-
erable in Hispanic patients with non-squamous NSCLC. This regimen was associated with
acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We
found a role for Ki67 and TS expression as prognostic factors.
Introduction
Lung cancer (LC) is the leading cause of cancer-related mortality worldwide. According to the
International Agency for Research on Cancer (IARC), the incidence of LC in 2012 was 23.1
cases per 105, while the case fatality ratio was 19.7 deaths per 105. LC corresponds to 13% of all
cancer cases and 19% of all cancer deaths [1]. In Colombia, LC is the third most common can-
cer after prostate and gastric cancer [1]. Despite the increasing efforts in novel screening tech-
niques and global awareness, most patients are diagnosed at advanced non-surgical stages;
thus, only 16.8% of patients survive at 5 years [2].
Research has highlighted the importance of LC histology on the treatment decision. The
most frequent histological subtype of non-small cell lung cancer (NSCLC) is adenocarcinoma,
comprising 55% of all cases [3]. The management of advanced NSCLC, particularly the non-
squamous subtype, has changed in the past decade due to the discovery of molecular markers
that influence the biological behavior of the disease and are now targets of cancer therapy [4,5].
For example, the identification of the activating mutation of Epidermal Growth Factor Recep-
tor (EGFR) as a predictive feature for tyrosine kinase inhibitors (TKIs) led to the establishment
of TKIs as the first-line treatment for EGFR-positive NSCLC [6–11].Additionally, the descrip-
tion of anaplastic lymphoma kinase (ALK) rearrangement supported the development of TKIs
against ALK, which are currently the first-line therapy for patients with ALK translocation
[12]. Interestingly, ALK treatments were developed faster (4 years) than the other targeted
therapies for NSCLC that became available for clinical use only after 10 years [13,14].
Although molecular biology and the development of targeted therapies have significantly
progressed, approximately half of the patients lack specific molecular mutations. Furthermore,
even when we identify certain molecular mechanisms, specific therapies for certain common
mutations are still missing (e.g., RAS) [13].
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Platinum-based chemotherapy remains the standard therapy for patients lacking EGFR
mutations or ALK translocations; such regimen has been shown to improve both quality of life
and survival risk death reduction; HR, 0.77; (95% CI, 0.71–0.83; P = .0001) [15]. This chemo-
therapy in combination (doublets) is recommended for patients with NSCLC and Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of either 0 or 1 [16,17]. How-
ever, for a subgroup of patients with non-squamous NSCLC, certain platinum combinations
are thought to be more effective than others. Platinum combinations with pemetrexed were
documented to be better than other platinum-based regimens for advanced lung adenocarci-
noma [18]; as such, these are the standards of care for non-squamous NSCLC [16,17].
Moreover, in different phase III trials the addition of bevacizumab to chemotherapy and its
continuance as maintenance therapy improved progression-free survival (PFS) compared with
chemotherapy alone [19–21]. Furthermore, patients without disease progression who received
four to six chemotherapy cycles of these agents and then continued with pemetrexed with or
without bevacizumab (maintenance therapy) had better outcomes as demonstrated by pro-
longed Progression-free survival (PFS) and increased overall survival (OS) compared with a
watch and wait strategy [22–25].
There is growing interest in developing biomarkers for predictive purposes regarding LC
chemotherapy. Research has suggested that thymidylate synthase (TS) expression, an enzy-
matic complex that participates in folate synthesis, could be used as a surrogate for the treat-
ment response to pemetrexed [26,27]. In vitro studies have supported this theory since LC cell
lines with low TS expression are highly sensitive to pemetrexed [28–30].
The main objective of this retrospective cohort was to describe the efficacy and safety of the
carboplatin/pemetrexed/bevacizumab regimen (PCB) followed by maintenance therapy (in
stable patients) with pemetrexed/bevacizumab (PB) in a real-life scenario of Hispanic adult
patients with advanced non-squamous NSCLC. Our secondary objective was to analyze TS
protein and mRNA expression and their association with clinical outcomes.
Subjects and Methods
Patient characteristics and tumor samples
One hundred forty-four lung adenocarcinoma chemotherapy-naïve patients who received at
least one cycle of PCB (the treatment included 4 cycles of induction with pemetrexed 500 mg/
m2, carboplatin AUC of 5, and bevacizumab 7.5 mg/kg intravenously every 3 weeks followed
by maintenance pemetrexed and bevacizumab at identical doses until disease progression or
intolerance) were included for the evaluation of: i) the treatment response, ii) safety, and iii)
toxicity. Eligibility for the regimen was determined by the treating oncologist who considered
standard bevacizumab inclusion criteria (absence of hemoptysis, hemorrhagic brain metastasis,
cavitation or involvement of large blood vessels). All of the study cases had complete clinical
records and available tissue for histologic review and immunohistochemistry. Given the budget
limitation, we performed molecular analysis (EGFR mutations, ALK translocations, TS protein
and mRNA expression) in 74 patients. Cases were collected from the p-Platform of the Foun-
dation for Clinical and Applied Cancer Research (FICMAC, Bogota, Colombia) fromMay 2010
to January 2015. Our study was approved by Clinica del Country Institutional Scientific and
Ethic Committee (R023-2014). All participants provided a written informed consent for inclu-
sion and use of tumor tissue and clinical information. Written consents were stored in file.To
secure confidentiality, a blinded independent staff member removed personal identification
indicators from histologic material. The clinical data were compared and analyzed through
codification.
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Microdissection, RNA isolation, and reverse transcription
One 10-μm-thick section was used for RNA extraction. The section was serial to three previous
sections, each 4-μm thick, from the same formalin-fixed paraffin-embedded tumor block that
was used for H&E staining to select appropriate neoplastic areas and for Ki67 and TTF1 immu-
nohistochemistry. The 10-μm-thick section was dried at 56°C overnight, deparaffinized, and
stained with Nuclear Fast Red solution (Nuclear fast red ab146372; ABCAM, San Francisco,
CA, USA), and then it was hydrated through graded alcohols and microdissected.
Quantitative real-time PCR
Quantitative PCR was performed using the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) in a 384-well plate. All quantitative PCR mixtures
contained 1 μL of cDNA template (<20 ng of reverse transcribed total RNA) diluted in 9 μL
of distilled-sterile water, 1,200 nmol/L of each primer, 200 nmol/L of internal probe, and the
TaqMan Gene Expression Master Mix (Applied Biosystems) for a final volume of 20 μL. The
sequences of the primers and probes for TS and the β-actin reference gene were as follows: TS
forward: 50-GGCCTCGGTGTGCCTTT-30, TS reverse: 50-GATGTGCGCAATCATGTACGT-30, TS
probe: (FAM)-50-AACATCGCCAGCTACGCCCTGC-30-(TAMRA); E2F1 forward: 50-CTCCA
AGCCGTGGACTCTT-30, E2F1 reverse: 50-ACATCGATCGGGCCTTGT-30, E2F1 probe: (FAM)-
50-CGGAGAACTTTCAGATCTCCCTTAAGAGCA-30(TAMRA); β-actin forward: 50-TGAGCG
CGGCTACAGCTT-30, β-actin reverse: 50-TCCTTAATGTCACGCACGATTT-30, β-actin probe:
(FAM)-50-ACCACCACGGCCGAGCGG-30-(TAMRA). Cycling conditions were 50°C for 2 min,
95°C for 10 min followed by 46 cycles at 95°C for 15 s, and 60°C for 1 min. Baseline and thresh-
old for cycle threshold (Ct) calculation were set manually using ABI Prism SDS 2.1 software. A
mixture containing Human Total RNA (Stratagene, Santa Clara, CA, USA) was used as the
control calibrator on each plate. EGFR mutations and ALK translocations were studied using
COBAS 8100 (Cobas real-time PCR platform; Roche Diagnostics, Indianapolis, IN, USA) and
fluorescence in situ hybridization (Vysis ALK Break Apart; Abbott Molecular, Des Plaines, IL,
US). RT–PCR for mRNA TS was preformed for all study participants (n = 144); while immu-
nohistochemistry was done for TS protein expression in 77 patients.
Immunohistochemistry
Serial 5-μm-thick sections were collected into charged slides. After paraffin removal, rehydra-
tion through graded alcohols, and endogenous peroxidase activity quenching, the sections
were treated in a pressure cooker for 5 min at 125°C, followed by a quick 10-s step at 90°C
using EDTA buffer (pH 8.0). The slides were then incubated for 40 min at room temperature
with primary mouse anti-TS antibody (clone 106; dilution, 1:100; Zymed), anti-Ki67 (clone
MIB-1; dilution, 1:150; Dako) and TTF-1 (dilution, 1:75; anti-TTF1 antibody; ab76013,
ABCAM, San Francisco, CA, USA). To assess TS immunostaining, the percentage of positive
tumor cells was scored semiquantitatively as follows: low, if TS-positive cells were<10%; mod-
erate, if TS-positive cells were between 11% and 39%; and high if TS-positive cells were>40%.
The intensity of the expression index of Ki67 was divided into the following groups:<20%: low,
20–30%: high,>30%: very high.
Statistical Analysis
For descriptive purposes, continuous variables were summarized as arithmetic means, medians
and standard deviations. Categorical variables were reported as proportions with 95% confi-
dence intervals (95% CIs). Inferential comparisons were performed using Student’s t test, χ2 or
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Fisher’s exact test were used to assess the significance among categorical variables. The time-
to-event variables obtained from the Kaplan-Meier method were determined by log-rank tests.
To test the association between TS mRNA expression (continuous variable) and clinicopatho-
logic features (dichotomous variables), the Kruskal-Wallis and Mann-Whitney U tests were
used. Statistical significance was determined as p0.05 using a two-sided test. All of the statisti-
cal analyses were performed using SPSS version 19.0 (SSPSS, Inc., Chicago, IL, US). In order to
validate our results, we compared survival outcomes between our study population and a retro-
spective control group of 72 patients with advanced NSCLC who received CBP-PEM between
2011 and 2012. Groups were matched for demographic characteristics (S1 Table).
Results
Patients Characteristics
The cohort included 144 Colombian patients who received PCB followed by PB for mainte-
nance therapy. The median age was 64 years (range, 32–86 years), 61% were female, and 65.3%
had some history of tobacco exposure. All of the patients had predominantly adenocarcinoma
on histologic analysis (97%). The performance status (PS) recorded by the Karnofski scale was
>70% in 90% of the patients. Forty-three patients (30.5%) had brain metastases, 19 patients
(13.5%) were treated with fractionated stereotactic radiosurgery (<6 lesions), 20 received cra-
nial whole-brain radiotherapy, and 4 underwent both interventions. Only 3 patients had sur-
gery. In these cases, bevacizumab was administered after the second or third cycle to minimize
the risk of bleeding in every patient (Table 1).
Twelve cases were EGFR (n = 9) or ALK (n = 3) positive; these patients started the PCB regi-
men after genotyping confirmation and directed therapy availability. The mean number of
PCB cycles before starting TK inhibitors was 2 and 8 for patients with EGFR mutations and
ALK/EML4 translocations, respectively. Ten of these patients (83.3%) presented early complete
or partial responses lasting 10.1 months (95% CI, 2.2–25.6) and had a median OS of 19.4
months (95% CI, 6.6–36.5). According to the Ki67 index, 43, 44 and 57 patients had an expres-
sion level of<20%, 20–30%, and>30%, respectively.
Response and survival analysis
The median follow-up was 13.8 months, and the median number of maintenance cycles was 6
(range, 1–32). Among the patients assessable for a response, the overall response rate (ORR)
was 66% (95% CI, 47% to 79%) and 15.3% achieved stable disease. Clinical improvement and
symptomatic relief were noted in 41% of the patients and clinical stability in another 40%. The
response was greater in women (p = 0.002), among former and nonsmokers (p = 0.021), in
those who had less than 10% weight loss within six months (p = 0.039), and in those who
received> 5 cycles (p = 0.003). The median progression-free PFS and OS rates were 7.9
months (95% CI, 5.9–10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respec-
tively (Fig 1). The median OS for the former and nonsmokers was slightly longer than for the
smokers (22.2 vs. 16.4 months, respectively; p = 0.049). The prognostic significance of Ki67 was
determined by a median OS of 30.6 months (95% CI, 27.7–33.4), 22.0 months (95% CI, 18.1–
25.8) and 8.3 months (95% CI, 6.6–10.0) among those who had an expression level<20%,
between 21 and 30%, and>30% (p = 0.002), respectively. The actuarial OS was longer among
those who achieved a complete or partial response [median, 25.5 months (95% CI, 22.7–28.4)]
versus the group of patients who progressed during PCB [median, 9.3 months (95% CI, 6.6–
11.9); p = 0.0001]. PFS was longer among patients with better performance status Karnosfky
Index (KI)>70%, median: 8.5 months (95% CI, 6.3–10.7) vs. KI<79%, median: 2.4 months
(95% CI, 0.8–4.1); p = 0.0001], in those who received more than 5 cycles [median, 6.2 months
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Table 1. Patient characteristics.
Variable N = 144 (%)
Age
Mean, SD 64 (+/-10.5)
<40 years 2 (1.4)
41–60 years 57 (39.6)
61–80 years 75 (52.1)
>80 years 10 (6.9)
Gender
Female 88 (61.1)
Male 56 (38.9)
Histology
Adenocarcinoma 140 (97.2)
NOS 4 (2.8)
Tobacco exposure
Smoker 15 (10.4)
Former smoker 79 (54.9)
Never smoker 39 (27.1)
No data 11 (7.6)
Number of chemotherapy cycles
<4 cycles 61 (42.4)
>5 cycles 83 (57.6)
EGFR mutation status
Mutated 9 (6.3)
Wild type 101 (70.1)
No data 34 (23.6)
ALK traslocation
Present 3 (2.1)
Absent 70 (48.6)
Not available 71 (49.3)
Number of organs affected
<2 125 (86.8)
>2 19 (13.2)
Pleural metastases/Pleural effusion
Present 51 (35.4)
Absent 93 (64.6)
Lung metastases
Present 83 (57.6)
Absent 61 (42.4)
Brain metastases/Leptomeningeal disease
Present 43 (29.9)
Absent 101 (70.1)
Bone metastases
Present 67 (46.5)
Absent 77 (53.5)
Liver metastases
Yes 48 (33.3)
No 96 (66.7)
Ki67
(Continued)
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(95% CI, 5.0–7.3) vs.4 cycles 1.9 months (95% CI, 0.7–3.0); p = 0.0001], and in the group
with the lowest expression level of Ki67 [<20%, median: 7.8 months (95% CI 0.0–18) vs. 20–
30%, median: 6.0 months (95% CI, 5.2–6.7) vs.>30%, median: 2.9 months (95% CI, 1.8–4.1);
p = 0.0001] (Fig 2).
In our study, we documented that Bevazizumab addition had a favorable impact insubjects
who received PCB had an increase of 6.9 months in OS compared to the control group (CBP/
Pem)(HR 0.64, CI95% 0.59–0.83; p = 0.016). The increase in OS was also observed (15 months)
in patients with low expression of mRNA (HR 0.49, 95%CI 0.43–0.62; p = 0.002); similarly the
OS in patients with low TS protein expression was 13.5 months (HR 0.76, 95%CI 0.69–0.88;
p = 0.03). Regarding PFS, there was a 2.8 months difference between our study group vs. the
historic control group, which was also significant (HR 0.82, 95%CI 0.80–0.94; p = 0.048).
Table 1. (Continued)
Variable N = 144 (%)
<20% 43 (29.9)
21–30% 44 (30.6)
>30% 57 (39.6)
TTF1
Positive 98 (68.1)
Negative 30 (20.8)
ND 16 (11.1)
TS protein expression levels (N = 74)
Negative 36 (48.6)
10–39% 18 (24.3)
>40% 20 (27.0)
doi:10.1371/journal.pone.0154293.t001
Fig 1. Kaplan Meier Curves for Overall Survival and Progression Free Survival.
doi:10.1371/journal.pone.0154293.g001
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Likewise there was an increase in PFS in those who received PCB and had low TS protein
expression compared to the control group (HR 0.97, 95%CI 0.94–1.32; p = 0.056).
Toxicity
Grade 2 and 3 toxicities attributable to the PCB regimen included anemia (29% and 10%,
respectively), fatigue (42% and 14%, respectively), febrile neutropenia (6%; grade 3 only),
thrombocytopenia (26% and 3%, respectively), and thromboembolic disease (4.1% and 2.0%,
respectively). The reported side effects (any grade) from bevacizumab included headache (20%),
epistaxis (34%), hemoptysis (3.7%), muscular weakness (12%), transient erythema (19%), and
hypertension (28%). Only one patient presented with bowel perforation and another had spon-
taneous tracheal rupture and secondary pneumomediastinum, likely secondary to bevacizumab.
TS expression response and correlation with clinical outcomes
TS correlation was performed in 74 patients with a mean age of 64.1 years (range, 32–86
years), and 82.5% were former or nonsmokers and had a median TS mRNA level of 1.45
Fig 2. Overall survival according to Ki67.
doi:10.1371/journal.pone.0154293.g002
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(range, 0.17–2.52). Stratifying the levels of TS mRNA by the median in 44.6% of the patients,
the results showed high TS mRNA expression. The level of TS mRNA expression was not asso-
ciated with tobacco exposure (p = 0.40), age (p = 0.37) or PS (p = 0.62). The TS mRNA levels
were significantly higher among patients with Ki67>30% (p = 0.0001) (Fig 2) and in those
with a negative TTF1 (p = 0.006). The TS mRNA levels (p = 0.18) and protein expression
(p = 0.51) did not influence the treatment response; however, OS was significantly higher in
patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2–32.9)] than in
patients with higher levels [median, 9.3 months (95% CI, 6.6–12.0); p = 0.0001] (Fig 3a). The
same trend occurred for PFS [lower TS mRNA levels vs. higher TS mRNA levels: median, 7.3
months (95% CI, 6.1–8.5) vs. 3.1 months (95% CI 2.6–3.5), respectively; p = 0.0001] (Fig 3b).
In addition, after classifying patients according to TS expression levels (10%, 11% to 39%,
and> 40%), we found that OS and PFS decreased with increasing TS expression levels (log-
rank p = 0.0001; Fig 4a and 4b). The OS when TS expression is10% was 28 months (95%CI
24.1–31.8), for the subgroup with TS expression level between 11% to 39% OS was 15.5 months
(95% CI, 12.7–18.4); p = 0.0001], while the median OS for the TS>40% subgroup decreased
significantly to 13.7 months (95% CI, 10.7–16.7) (Fig 5).
Importantly, in multivariate analysis, the TS mRNA, TS protein expression level and num-
ber of maintenance cycles modified OS (p = 0.017, p = 0.047 and p = 0.002, respectively).
Moreover, we found a significant correlation between the TS mRNA levels and protein expres-
sion (p = 0.002).
Discussion
To our knowledge, this is the first study describing the efficacy and safety of PCB chemother-
apy in a Hispanic population with non-squamous NSCLC. The median OS (21.4 months) in
our series was superior to that of previous reports with doublet platinum-based plus bevacizu-
mab regimens with maintenance (median OS, 11.7 to 17.1 months) [24,25,31]. Barlesi et al., in
a phase III trial, demonstrated that induction chemotherapy with cisplatin/pemetrexed/bevaci-
zumab followed by maintenance with PB had superior PFS rates (difference of 3.6 months)
Fig 3. Kaplan-Meier Curves for Overall Survival and Progression Free Survival according to TSmRNA levels.
doi:10.1371/journal.pone.0154293.g003
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compared with maintenance therapy with bevacizumab alone in patients with non-squamous
NSCLC. The authors documented that patients who received maintenance therapy with PB
and had stable disease during induction regimen had a tendency to have better OS (4
months); however, this improvement, was not statistically significant [24, 32]. Furthermore,
the authors reported that PFS in the PB arm was 7.4 months, which is slightly inferior to our
results (7.9 months). After analyzing other endpoints, Barlesi et al. found an ORR of 55% (95%
CI, 46–59.1%), also inferior to our data (ORR of 65% with 95% CI, 47%-79%) [32]. In contrast,
in our study there were no differences in the proportion of patients who received second-line
therapy (treatment after progression; 70.5% vs. 86%), which would not explain the difference
in survival between these two studies [32].
Similarly, Patel et al. compared PCB as an induction regimen followed by PB (study arm)
with carboplatin/paclitaxel/bevacizumab as induction chemotherapy followed by maintenance
with bevacizumab (control arm). The authors did not find significant differences in the pri-
mary endpoint (OS); nevertheless, they described a 0.4-month PFS improvement favoring the
study arm [25]. After comparing the endpoints between Patel’s study, we documented superior
OS and PFS (12.6 vs. 21.4 months and 6 vs. 7.9 months, respectively), additionally we found
better ORR (34.1 vs. 65%). In terms of PFS and ORR, it is likely that our improved outcomes
are the result of the extended OS. However, since we did not have a control arm, comparing
our data with other studies has important inherent limitations.
In a similar study design, Liu andWu retrospectively reviewed the effect of cisplatin, peme-
trexed, and bevacizumab with a median of 4 cycles. The investigators did not administer main-
tenance therapy and observed an equal frequency of partial response and stable disease. The
ORR was 43%, the median PFS was 5.2 months (95% CI, 3.7 to 6.7 months), and the median
OS was 11.4 months (95% CI, 8.8 to 13.9 months) [38]. In contrast, we only administered car-
boplatin, which is the standard of care, and compared with cisplatin, has a better safety profile
[33].
Fig 4. Kaplan Meier Curves according to TS protein expression.
doi:10.1371/journal.pone.0154293.g004
Pemetrexed/Carboplatin/Bevacizumab for Stage IV Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0154293 May 18, 2016 10 / 15
PRONOUNCE is a phase III trial with a similar methodologic design to that of the Patel
study. In this trial, 361 patients were randomized to receive carboplatin/pemetrexed followed
by pemetrexed as maintenance therapy or PCB followed by bevacizumab as maintenance ther-
apy [34]. The primary endpoint of this study was PFS without grade 4 toxicity (PFS G4); the
authors did not find differences in the primary or secondary endpoints (OS, PFS) between the
two treatment strategies. Compared with the PRONOUNCE trial, we documented better clini-
cal outcomes, however our study lacked a control arm.
The toxicity profile encountered in our cohort is similar to that of previous studies. Accord-
ing to the literature, PCB followed by PB is a well-tolerated regimen with acceptable toxicity
that is rarely fatal. In our study, grade 3 toxicity was the most commonly documented hemato-
logic toxicity. We commonly reported neutropenia and anemia, the frequencies of which were
similar to those found in other studies [23,25,32,34]. In accordance with other trials, the most
frequent non-hematological grade 3 toxicity was fatigue (11% vs. 2.4 to 10.9%)[25,32,34]. Nei-
ther hemorrhagic nor thromboembolic grade3 events associated with bevacizumab were
present in our series; however, we observed a case of gut perforation and a case of tracheal
rupture.
Fig 5. Overall survival according to TS protein expresson level (stratified).
doi:10.1371/journal.pone.0154293.g005
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TS expression is recognized as a predictive factor for the response to pemetrexed. Two
meta-analyses have evaluated such relationship; Wang et al. analyzed 526 NSCLC patients
from eight clinical trials that assessed TS expression and the ORR to pemetrexed. The authors
documented superior ORR in patients with low TS expression (Odds Ratio = 0.45; 95% CI,
0.29–0.70; p = 0.0004). A low level of TS expression was also associated, with better PFS and
OS, albeit the latter was not statistically significant [35]. Similarly, Liu et al. evaluated the asso-
ciations between TS expression, PFS and OS in eight studies of patients treated with peme-
trexed. The authors also suggested that patients with low TS expression had better PFS and OS
than patients with higher TS levels (PFS: HR = 0.63; 95% CI, 0.52–0.76; OS: HR = 0.74, 95% CI,
0.63–0.88) [36]. We also reported that low TS expression was associated with better clinical
outcomes (OS) and confirmed the usefulness of TS expression as a prognostic factor. However
in the population we analyzed (n = 79), TS expression (mRNA levels and protein expression)
did not influence the treatment response. Likewise, a recently published Phase II trial by Sun
et al. evaluated TS as a predictive marker for the clinical outcome of NSCLC patients after
treatment determined the status of TS expression. A total of 341 subjects were stratified accord-
ing to TS expression (defined as negative or positive) and received either pemetrexed/cisplatin
or gemcitabine/cisplatin for a maximum of 6 cycles until disease progression. The authors
documented that pemetrexed/cisplatin was superior to gemcitabine/cisplatin based on the
response rate and PFS, (47% vs. 21%, P = 0.008) in the TS-negative group. Moreover, the
median OS time of all TS-negative group patients was significantly longer than the OS time of
patients in the TS-positive group (30.3 vs. 15.2 months, respectively; HR, 0.50; 95% CI, 0.36 to
0.70) [37]. Consistent with our cohort results, this finding suggested that low TS expression is
associated with a better OS.
Additionally, our study also supported Ki67, as a prognostic factor; since lower Ki 67 expres-
sion was associated with longer OS. This is consistent with a previous meta-analysis of 32 stud-
ies involving 5600 Asian patients; in such study the authors established that elevated Ki 67 was
also linked to poorer outcomes in NSCLC [38].
Our study limitations include lack of a control arm and small sample size; in a forthcoming
study it will be important to analyze the association of tumor heterogeneity and the predictive
value of both TS and Ki 67.
Conclusions
PCB followed by PB was effective and safe in our study group. This regimen was associated
with acceptable toxicity and with prolonged OS. In our cohort both Ki67 and TS expression
were important prognostic biomarkers.
Supporting Information
S1 Dataset. Patient data base.
(SAV)
S1 Table. Characteristics of control group.
(DOCX)
Acknowledgments
CLICAP members: Oscar Arrieta, Andrés Cardona, Leonardo Rojas, Mauricio Cuello, Luis
Corrales, Claudio Martín.Oscar Arrieta, principal investigator of CLICAP, Frequency of ALK
Rearrangements in Non Small-Cell Lung Cancer in Latin America: The Latin-American Con-
sortium for the Investigation of Lung Cancer (CLICaP). ogarrieta@gmail.com
Pemetrexed/Carboplatin/Bevacizumab for Stage IV Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0154293 May 18, 2016 12 / 15
Disclaimer: Preliminary results from this study were previously shared during the 2014
LALCAMeeting (August 21–23, 2014 Lima, Peru) and the 16th World Conference on Lung
Cancer (September 4–9, 2015 Denver, Colorado, USA).
Author Contributions
Conceived and designed the experiments: AFC LR RR. Contributed reagents/materials/analysis
tools: OA HC CV JO. Wrote the paper: AFC LR BWMC LC CM CO SF RR.
References
1. Cancer IARC. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in
2012. In, 2012.
2. Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C et al. Overview of breast cancer collabo-
rative stage data items—their definitions, quality, usage, and clinical implications: a review of SEER
data for 2004–2010. Cancer 2014; 120 Suppl 23: 3771–3780. doi: 10.1002/cncr.29059 PMID:
25412389
3. Scrump DC DK CR, Marks LB Giaccone G. Non-Small Cell Lung Cancer. In: DeVita VT L T, Rosenberg
SA editor Cancer: Principles and Practice of Oncology. Philadelphia: Wolters Kluwer/Lippincott Wil-
liams &Wilkins, 2011.
4. PaoW, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175–180.
doi: 10.1016/S1470-2045(10)70087-5 PMID: 21277552
5. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key
pathways in lung adenocarcinoma. Nature 2008; 455: 1069–1075. doi: 10.1038/nature07423 PMID:
18948947
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. North-East Japan Study
G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;
362: 2380–2388. doi: 10.1056/NEJMoa0909530 PMID: 20573926
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957. doi: 10.1056/NEJMoa0810699 PMID:
19692680
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. West Japan Oncology G.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring muta-
tions of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Lancet Oncol 2010; 11: 121–128. doi: 10.1016/S1470-2045(09)70364-X PMID: 20022809
9. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line
treatment for patients with advanced EGFRmutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–
742. doi: 10.1016/S1470-2045(11)70184-X PMID: 21783417
10. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based
chemotherapy for EGFRmutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analy-
sis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–151. doi:
10.1016/S1470-2045(14)71173-8 PMID: 25589191
11. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Spanish Lung Cancer
Group in collaboration with Groupe Francais de P-C, Associazione Italiana Oncologia T. Erlotinib ver-
sus standard chemotherapy as first-line treatment for European patients with advanced EGFRmuta-
tion-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3
trial. Lancet Oncol 2012; 13: 239–246. doi: 10.1016/S1470-2045(11)70393-X PMID: 22285168
12. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA,
Costa DB, Varella-Garcia M, KimWH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, TanW,
Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber
DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-
small-cell lung cancer. N Engl J Med 2010; 363: 1693–1703. doi: 10.1056/NEJMoa1006448 PMID:
20979469
13. Gandara DR, Li T, Lara PN Jr., Mack PC, Kelly K, Miyamoto S, et al. Algorithm for codevelopment of
new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
Clin Lung Cancer 2012; 13: 321–325. doi: 10.1016/j.cllc.2012.05.004 PMID: 22677432
14. Pickl M, Ruge E, Venturi M. Predictive markers in early research and companion diagnostic develop-
ments in oncology. N Biotechnol 2012; 29: 651–655. doi: 10.1016/j.nbt.2012.03.008 PMID: 22484859
Pemetrexed/Carboplatin/Bevacizumab for Stage IV Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0154293 May 18, 2016 13 / 15
15. Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-
cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized
controlled trials. J Clin Oncol 2008; 26: 4617–4625. doi: 10.1200/JCO.2008.17.7162 PMID: 18678835
16. Azzoli CG, Temin S, Aliff T, Baker S Jr., Brahmer J, Johnson DH, et al. Focused Update of 2009 Ameri-
can Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV
Non-Small-Cell Lung Cancer. J Clin Oncol 2011; 29: 3825–3831. doi: 10.1200/JCO.2010.34.2774
PMID: 21900105
17. Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, et al. Central European
Cooperative Oncology G. Third CECOG consensus on the systemic treatment of non-small-cell lung
cancer. Ann Oncol 2012; 23: 1223–1229. doi: 10.1093/annonc/mdr381 PMID: 21940784
18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study
comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients
with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–3551. doi: 10.1200/JCO.
2007.15.0375 PMID: 18506025
19. Johnson DH, Fehrenbacher L, NovotnyWF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized
phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel
alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol
2004; 22: 2184–2191. PMID: 15169807
20. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Group BOS. Overall sur-
vival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous
non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:
1804–1809. doi: 10.1093/annonc/mdq020 PMID: 20150572
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550. PMID:
17167137
22. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed
plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a
randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432–1440. doi: 10.1016/S0140-6736(09)
61497-5 PMID: 19767093
23. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with
pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy
with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARA-
MOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247–255. doi:
10.1016/S1470-2045(12)70063-3 PMID: 22341744
24. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikstrom A, Chouaid C, et al. Maintenance bevaci-
zumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-
small-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III
trial. Ann Oncol 2014; 25: 1044–1052. doi: 10.1093/annonc/mdu098 PMID: 24585722
25. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized
phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed
and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance beva-
cizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;
31: 4349–4357. doi: 10.1200/JCO.2012.47.9626 PMID: 24145346
26. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther
2003; 3: 145–156. PMID: 12722874
27. WuMF, Hsiao YM, Huang CF, Huang YH, YangWJ, Chan HW, et al. Genetic determinants of peme-
trexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol
2010; 5: 1143–1151. doi: 10.1097/JTO.0b013e3181e0b954 PMID: 20559153
28. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH, et al.Pemetrexed induces both intrinsic
and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signal-
ing pathways. Mol Carcinog 2013; 52: 183–194. doi: 10.1002/mc.21842 PMID: 22086658
29. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, et al.Significance of thymidylate synthase
for resistance to pemetrexed in lung cancer. Cancer Sci 2010; 101: 161–166. doi: 10.1111/j.1349-
7006.2009.01358.x PMID: 19811498
30. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-
squamous lung cancer. Lung Cancer 2009; 66: 141–149. doi: 10.1016/j.lungcan.2009.06.006 PMID:
19577816
31. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo et al.Squamous cell carcinoma of
the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidy-
late synthase. Cancer 2006; 107: 1589–1596. PMID: 16955506
Pemetrexed/Carboplatin/Bevacizumab for Stage IV Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0154293 May 18, 2016 14 / 15
32. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al.Randomized phase III trial
of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab,
cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL
(MO22089). J Clin Oncol 2013; 31: 3004–3011. doi: 10.1200/JCO.2012.42.3749 PMID: 23835708
33. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.Eastern Cooperative Oncol-
ogy G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J
Med 2002; 346: 92–98. PMID: 11784875
34. Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, et al. PRO-
NOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by
maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bev-
acizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015; 10:
134–142. doi: 10.1097/JTO.0000000000000366 PMID: 25371077
35. Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H. The pemetrexed-containing treatments in the non-
small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase
expression: a meta-analysis. BMCCancer 2014; 14: 205. doi: 10.1186/1471-2407-14-205 PMID:
24641970
36. Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical
outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review
and meta-analysis. Cancer Chemother Pharmacol 2013; 72: 1125–1132. doi: 10.1007/s00280-013-
2299-2 PMID: 24067998
37. Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, et al.Pemetrexed Plus Cisplatin Versus Gemcitabine
Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung
Cancer: A Biomarker-Stratified Randomized Phase II Trial. J Clin Oncol 2015; 33: 2450–2456. doi: 10.
1200/JCO.2014.59.9324 PMID: 26124486
38. Wen S, ZhouW, Li CM, Hu J, Hu XM, Chen P, et al. Ki-67 as a prognostic marker in early-stage non-
small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC
Cancer. 2015, 15; 15:520. doi: 10.1186/s12885-015-1524-2 PMID: 26174366
Pemetrexed/Carboplatin/Bevacizumab for Stage IV Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0154293 May 18, 2016 15 / 15
